Alterity Therapeutics Limited (ASX:ATHO)

Market Cap	108.75M
Revenue (ttm)	5.44M
Net Income (ttm)	-12.15M
Shares Out	n/a
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	91,267
Average Volume	1,458,721
Open	0.0050
Previous Close	0.0060
Day's Range	0.0050 - 0.0050
52-Week Range	0.0010 - 0.0120
Beta	n/a
RSI	45.48
Earnings Date	Oct 29, 2025

About Alterity Therapeutics

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson’s disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multi...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1997
• Employees: 9
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: ATHO